Skip to main content

Table 1 Patient and treatment characteristics

From: Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era

  Total (n = 336) 3D-CRT (n = 186) IMRT (n = 150) P*
Age, years, median (range) 58 (16–79) 59 (16–79) 56 (16–79) 0.004
Sex, n (%)
 Female 149 (44.3) 96 (51.6) 53 (35.3) 0.003
 Male 187 (55.7) 90 (48.4) 97 (64.7)  
KPS, n (%)
  ≤ 70 172 (51.2) 104 (55.9) 68 (45.3) 0.156
 80 82 (24.4) 41 (22) 41 (27.3)  
  ≥ 90 82 (24.4) 41 (22) 41 (27.3)  
Extent of resection, n (%)
 Total 206 (61.3) 109 (58.6) 97 (64.7) 0.009
 Subtotal/Partial 108 (32.1) 70 (37.6) 38 (25.3)  
 Biopsy 22 (6.5) 7 (3.8) 15 (10)  
IDH1 mutation, n (%)
 No 250 (74.4) 117 (62.9) 133 (88.7) < 0.001
 Yes 18 (5.4) 6 (3.2) 12 (8)  
 unknown 68 (20.2) 63 (33.9) 5 (3.3)  
MGMT, n (%)
 Unmethylated 212 (63.1) 115 (61.8) 97 (64.7) 0.592
 Methylated 124 (36.9) 71 (38.2) 53 (35.3)  
Subventriclular zone, n (%)
 Uninvolved 206 (61.3) 122 (65.6) 84 (56) 0.073
 Involved 130 (38.7) 64 (34.4) 66 (44)  
PTV1 volume, cm3, median (range) 403 (71–1080) 422 (74–1080) 375 (71–1041) <.001
PTV2 volume, cm3, median (range) 113 (6–475) 119 (12–475) 103 (6–468) 0.002
Total dose, Gy, median (range) 60 (41–72.5) 60 (54–70) 60 (41–72.5) 0.073
No. of fractionation, median (range) 30 (15–35) 30 (23–35) 30 (15–33) <.001
Baseline TLC, /μL, median (range) 1370 (300–3740) 1365 (300–3740) 1385 (410–3640) 0.648
Baseline TLC, /μL, n (%)
  < 1000 81 (24.1) 45 (24.2) 36 (24) 0.893
  ≥ 1000 255 (75.9) 141 (75.8) 114 (76)  
The cumulative dose of temozolomidea, mg/m2, median (range) 3588 (722–6267) 3497 (856–6267) 3684 (722–5599) 0.117
  1. Abbreviations: 3D-CRT three-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, KPS Karnofsky performance status, PTV planning target volume, TLC total lymphocyte count
  2. *P-values were calculated for the comparison of the 3D-CRT and IMRT groups
  3. aThe cumulative doses of temozolomide for 3 months from the start of chemoradiation were calculated